|
[posting]62107652[/posting]Wikipedia: Rituximab is currently co-marketed by Biogen and Genentech in the U.S., by Hoffmann–La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran. Genentech Umsätze: Rituxan sales for 1998 were $162.6 million. In its first full year on the market, Rituxan was used to treat more than 16,000 patients worldwide and its first year of sales revenues exceeded that of any previously launched anti-cancer therapeutic. 1998: Genentech Income Up 70 Percent In Rituxan-Fueled 2nd Quarter 2/2002 Rituxan sales in 2001 increased 84 percent to $818.7 million from $444.1 million in 2000. This sales increase is due primarily to increased market penetration for the treatment of non-Hodgkin's lymphoma. Das mal als Indikation wie es gehen kann. |
|
| aus der Diskussion: | Morphosys: Setzen auf marktreife Partnerprojekte und dicke Meilensteine |
| Autor (Datum des Eintrages): | Basti99 (08.12.19 18:20:43) |
| Beitrag: | 7,509 von 27,227 (ID:62108003) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |